Ocugen rises as gene therapy shows promise for blinding eye disease

Ocugen

15/01/2026 13:26

** Shares of drugmaker Ocugen OCGN.O rise 2.7% to $1.93 premarket

** Co says experimental therapy, OCU410, slowed progression of geographic atrophy, a severe form of age-related macular degeneration

** About half the patients on therapy saw eye lesion growth reduced by 46% vs. no treatment, while a medium dose cut growth by 54% - OCGN

** Adds there were no serious side effects reported in the 51-patient mid-stage trial

** Plans larger late-stage trial in 2026; targets regulatory filing in 2028

** As of last close, stock up ~68% over the past year

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))